Amivantamab

Status:

Do Not Prescribe (DNP)

Decision Date:

January 2023

Comments

DNP: NICE TA850 - Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy

 

Black Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

search again